In December 2023, drug manufacturer Pfizer changed its strategic sales approach for nirmatrelvir/ritonavir (Paxlovid) by shifting to commercial sales in lieu of providing the COVID-19 antiviral drug at no-cost to patients exclusively through the federal government, according to Kaiser Health News. Some patients, such as those who are uninsured or enrolled in Medicare, Medicaid, may qualify for free prescription fills, but they need to work through an application process. What’s concerning is that nirmatrelvir/ritonavir has …
Read More
